Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, Chief Scientific Officer | March 15, 2013 | March 19, 2013 |
| CHIMERIX INCCMRX · Entity 80651 | Director | June 28, 2017 | June 29, 2017 |
| IQVIA HOLDINGS INC.IQV · Entity 3058 | Director | April 23, 2026 | April 27, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director · President and CEO | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date March 15, 2013 · Filed March 19, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 107,320 |
Ending reported balance
After 2013-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-03-15 · Exercise / conversion · Acquired 46,700 · Balance 154,020 Row 2 · 2013-03-15 · Sale · Disposed 46,700 · Balance 107,320 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.86 · Expires 2018-02-14 | Direct | 46,700 |
Reported balance
After 2013-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2013-03-15 · Exercise / conversion · Disposed 46,700 · Balance 46,700 |
| Common stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 6,473 |
Reported balance
Holding disclosure · report date 2013-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,473 F1: Balance in the AbbVie Savings Program as of March 15, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the AbbVie Savings Program as of March 15, 2013.
CHIMERIX INC
Report date June 28, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2027-06-27 | Direct | 21,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting.
IQVIA HOLDINGS INC.
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,946 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 1,571 · Balance 16,946 F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant.
Intellia Therapeutics, Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,147,064 |
Ending reported balance
After 2026-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-20 · Sale · Disposed 19,890 · Balance 1,149,849 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price. Row 2 · 2026-08-21 · Sale · Disposed 2,785 · Balance 1,147,064 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 58,415 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 58,415 F3: Shares held by the John M. Leonard 2015 Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
F3: Shares held by the John M. Leonard 2015 Irrevocable Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vitae Pharmaceuticals, Inc
Report date October 25, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.85 · Expires 2025-07-28 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 24, 2026 20:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,785 | $13.00 | $36,205.00 |
DisclosureSEC source: 0001193125-26-363567 · ownership.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,147,064 F1 · kind: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 19,890 | $12.60 | $250,614.00 |
DisclosureSEC source: 0001193125-26-363567 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,149,849 F1 · kind: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:03 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-027609 · wk-form4_1777323780.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,946 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 225,400 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001193125-26-088269 · ownership.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,400 Underlying: Common Stock · 225,400 shares Expires 2036-02-29 F3 · derivative.exercise_date: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 156,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088269 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,169,739 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 34,146 | $9.21 | $314,484.66 |
DisclosureSEC source: 0001193125-26-006294 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,013,339 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 8,557 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · derivative · entry 8 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,557 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 8,557 | $6.83 | $58,444.31 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · nonDerivative · entry 5 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,047,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 49,959 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · derivative · entry 7 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,557 Underlying: Common Stock · 49,959 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 5,355 | $9.59 | $51,354.45 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · nonDerivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,038,928 F1 · kind: The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 32,832 | $9.47 | $310,919.04 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,044,283 F1 · kind: The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 49,959 | $9.49 | $474,110.91 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,077,115 F1 · kind: The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:09 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 49,959 | $6.83 | $341,219.97 |
DisclosureSEC source: 0001193125-25-317551 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,127,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2025 Filed Apr 25, 2025 22:17 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-25-000072 · wk-form4_1745619471.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,375 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 196,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0000950170-25-032248 · ownership.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 Underlying: Common Stock · 196,000 shares Expires 2035-02-28 F3 · derivative.exercise_date: This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032248 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,077,115 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 26,807 | $12.18 | $326,509.26 |
DisclosureSEC source: 0000950170-25-003012 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 941,115 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-001236 · ownership.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,850 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 7,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-001236 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 967,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| May 07, 2024 Filed May 9, 2024 21:06 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-24-000079 · wk-form4_1715288757.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,783 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 163,929 | $0.00 Strike: $32.66 | $0.00 |
DisclosureSEC source: 0000950170-24-025900 · ownership.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,929 Underlying: Common Stock · 163,929 shares Expires 2034-02-28 F3 · derivative.exercise_date: This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 113,586 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025900 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960,072 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:51 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 19,223 | $29.46 | $566,309.58 |
DisclosureSEC source: 0000950170-24-002516 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,486 F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001197 · ownership.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,848 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 7,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-001197 · ownership.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 865,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| May 10, 2023 Filed May 12, 2023 21:20 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-23-000075 · wf-form4_168392643994809.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,736 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 128,631 | $0.00 Strike: $40.75 | $0.00 |
DisclosureSEC source: 0001209191-23-015764 · doc4.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,631 Underlying: Common Stock · 128,631 shares Expires 2033-02-28 F3 · derivative.exercise_date: This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 91,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015764 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857,861 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:32 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 6,673 | $37.21 | $248,302.33 |
DisclosureSEC source: 0001209191-23-002425 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,825 F1 · date: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001495 · doc4.xml · derivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,698 Underlying: Common Stock · 7,848 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F3 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 01:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 7,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001495 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:02 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-22-000072 · wf-form4_165247564402913.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,673 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 01, 2022 Filed Mar 5, 2022 02:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 59,941 | $0.00 Strike: $79.85 | $0.00 |
DisclosureSEC source: 0001209191-22-016537 · doc4.xml · derivative · entry 6 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,941 Underlying: Common Stock · 59,941 shares Expires 2032-02-28 F6 · derivative.exercise_date: This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 5, 2022 02:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 40,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016537 · doc4.xml · nonDerivative · entry 3 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,650 F3 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| January 01, 2022 Filed Mar 5, 2022 02:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016537 · doc4.xml · derivative · entry 5 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,546 Underlying: Common Stock · 7,848 shares Expires 2031-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. F5 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. Read SEC document |
| January 01, 2022 Filed Mar 5, 2022 02:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,493 | $112.26 | $279,851.72 |
DisclosureSEC source: 0001209191-22-016537 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,660 F2 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Mar 5, 2022 02:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 7,848 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016537 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 15,985 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · derivative · entry 22 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 15,985 shares Expires 2027-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 28,750 | $0.00 Strike: $23.46 | $0.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · derivative · entry 21 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,750 shares Expires 2028-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 44,735 | $170.00 | $7,604,950.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 16 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 15,985 | $18.30 | $292,525.50 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 15 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 28,750 | $23.46 | $674,475.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 14 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 37,833 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · derivative · entry 20 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 37,833 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 37,833 | $155.00 | $5,864,115.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 13 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 37,833 | $14.58 | $551,605.14 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 12 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 27,167 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · derivative · entry 19 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,833 Underlying: Common Stock · 27,167 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 11,637 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · derivative · entry 18 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,501 Underlying: Common Stock · 11,637 shares Expires 2030-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 216 | $160.69 | $34,709.04 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 11 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,305 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 725 | $159.98 | $115,985.50 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 10 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,521 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 00:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,598 | $159.18 | $413,549.64 |
DisclosureSEC source: 0001209191-21-054331 · doc4.xml · nonDerivative · entry 9 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,246 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.